8047-67-4O.O.O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Na+].[Na+].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[OH-]ADQSUDSYBZBMFT-JMMWHMDLNA-HIron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.
8047-67-4Breast Feeding; Lactation; Milk, Human; Ferric Compounds; Hematinics; Iron Compounds
Breast Feeding; Lactation; Milk, Human; Ferric Compounds; Iron Compounds
EMA approved medicines: Human medicine
Brown solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
◉ Summary of Use during Lactation
◉ Summary of Use during Lactation
V - Various
QV - Various
Following intravenous administration, iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron is then incorporated into hemoglobin as the cells mature into red blood cells.
SUCROFERRIC OXYHYDROXIDE
Phosphate Binder [EPC]; Phosphate Chelating Activity [MoA]
The intravensously administered iron sucrose injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.
Renal elimination of iron contributed very little to the total elimination (in average less than 5%). While, renal elimination of sucrose accounts for 68-75% of the administered dose after 4 and 24 hours respectively.
Vd is 7.3 L
Total body clearance is 20.5 ml/min.
용도Iron Saccharate has been used to treat iron deficiency and iron deficiency anemia associated with different chronic diseases.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…